Ventricular arrhythmias in chronic heart failure: features of treatment and the possibility of improving the prognosis

Cover Page

Cite item

Full Text

Abstract

Ventricular arrhythmias often complicate the course of chronic heart failure (CHF) and are one of the main causes of sudden cardiac death (VSS). The article presents current data on the management of patients with CHF with "potentially dangerous" ventricular arrhythmias, drug and non-drug methods of primary prevention of VSS, including the use of implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT). An important place in the presented work is devoted to the treatment of stable VT and improvement of the prognosis for life-threatening ventricular arrhythmias (VT/VF): indications for use of class III antiarrhythmic, ICD and catheter ablation. It was noted that for patients with CHF who have sustained VT or who survived after circulatory arrest (VF), the optimal treatment is CD implantation, rather than pharmacotherapy. The presented material is based on data from modern international guidelines (ESC, AHA/ACC/HRS) for the treatment of CHF, ventricular arrhythmias and SCD prevention, as well as the results of a number of controlled studies and own clinical experience in the treatment of arrhythmias.

About the authors

Yuriy A. Bunin

Russian Medical Academy of Continuous Professional Education

Email: yabunin@outlook.com
D. Sci. (Med.), Prof. Moscow, Russia

Elena A. Zolozova

Russian Medical Academy of Continuous Professional Education

Email: ezolozova@mail.ru
Cand. Sci. (Med.) Moscow, Russia

References

  1. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. doi: 10.1093/eurheart/ehw128
  2. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction. Eur Heart J 2012; 33: 1750-7.
  3. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-847.
  4. Maggioni A.P, Zuanetti G, Franzosi M.G et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312-22.
  5. Deyell M.W, Park K.M, Han Y et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9: 1465-72.
  6. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015. DOI: 10.1093eurheartj/ehv316
  7. Desai A.S, Mc Murray J.J, Packer M et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990-7.
  8. Kotecha D, Holmes J, Krum H et al. Beta-blockers in heart failure collaborative group. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation. Lancet 2014; 384: 2235-43.
  9. Bapoje S.R, Bahia A, Hokanson J.E et al. Effect of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 2013; 6: 166-73.
  10. Piccini J.P, Berger J.S, O’Connor C.M. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30 (10): 1245-53.
  11. Boutitie F, Boissel J-P, Connolly S.J. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT and CAMIAT databases. The EMIAT and CAMIAT investigators. Circulation 1999; 99 (17): 2268-75.
  12. Bardy G.H, Lee K.L, Mark D.B et al. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (2): 225-37.
  13. Velazquez E.J, Lee K.L, Deja M.A et al. STICH investigators. Coronary-artery bypass surgery in patients with ventricular dysfunction. N Engl J Med 2011; 364: 1607-16.
  14. Carson P, Wertheimer J, Miller A et al. The STICH trial: mode-of-death results. JACC Heart Fail 2013; 1: 400-8.
  15. NanthaKumar K, Epstein A.E, Kay G.N et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2004; 44 (11): 2166-72.
  16. Kadish A, Dyer A, Daubert J.P et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8.
  17. Desai A.S, Fang J.C, Maisel W.H, Baughman K.L. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874-9.
  18. AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. JACC doi: 10.1016/J.Jacc.2017.10.054
  19. Bristow M.R, Saxon L.A, Boehmer J et al. Comparison of medical therapy, pacing and defibrillator in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.
  20. Cleland J.G, Daubert J.C, Erdmann E. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49.
  21. Gasparini M, Leclercq C, Lunati M et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study. JACC Heart Fail 2013; 1: 500-7.
  22. Connolly S.J, Hallstrom A.P, Cappato R et al. Meta-analysis of the implantable cardioverter-defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J 2000; 21: 2071-8.
  23. Connoly S.J, Dorian P, Roberts R.S et al. Comparison of beta-blockers, amiodarone plusbeta-blockers or sotalol for prevention of shocks from implantable cardioverter-defibrillators. The OPTIC study. JAMA 2006; 295: 165-71.
  24. Tanner H, Hindricks G, Volkmer M et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010; 21: 47-53.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies